Key terms
About CLRB
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CLRB news
Mar 28
3:25pm ET
Buy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid Financials
Mar 28
8:18am ET
Cellectar Biosciences price target raised to $28 from $20 at Roth MKM
Mar 28
7:50am ET
Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS)
Mar 28
7:43am ET
Cellectar Biosciences price target raised to $12 from $11 at Oppenheimer
Mar 25
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
Mar 04
11:55am ET
Buy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Acquisition Potential
Mar 04
11:50am ET
Cellectar Bio reports ‘impressive’ efficacy in Phase 1 trial, says Roth MKM
Mar 04
6:43am ET
Cellectar Biosciences reports results from Phase 1 study of iopofosine I 131
Jan 31
10:56am ET
Biotech Alert: Searches spiking for these stocks today
Jan 31
8:30am ET
One new option listing and two option delistings on January 31st
Jan 30
6:45am ET
Cellectar Biosciences enrolls first patient in pediatric glioma Phase 1b study
Jan 26
4:43am ET
Cellectar Biosciences Exercises Tranche A Warrants for $44.1M
Jan 22
2:51pm ET
Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB), Ionis Pharmaceuticals (IONS) and CVRx (CVRX)
Jan 22
6:44am ET
Cellectar Biosciences’ iopofosine conjugate shows efficacy in CNS malignancies
Jan 11
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 11
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 11
6:42am ET
Cellectar Biosciences partners with AON
Jan 10
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Jan 09
12:00pm ET
Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB) and Seres Therapeutics (MCRB)
Jan 09
7:31am ET
Cellectar Biosciences price target raised to $11 from $8 at Oppenheimer
Jan 08
6:42am ET
Cellectar Biosciences says CLOVER WaM study met its primary endpoint
Jan 04
12:35pm ET
Buy Rating Backed by Pivotal Trial Catalyst and Novel Drug Delivery Platform for Cellectar Biosciences
No recent press releases are available for CLRB
CLRB Financials
Key terms
Ad Feedback
CLRB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CLRB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
